Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics Provides Baxdela NDA Update
February 27, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...
Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™
October 26, 2016 08:00 ET
|
Melinta Therapeutics
NEW ORLEANS, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections,...
Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
October 24, 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has...
Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting
June 14, 2016 12:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, June 14, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that...
Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections
May 12, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, May 12, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, today announced top-line results...
Melinta Therapeutics to Present at BioCentury Future Leaders Conference
March 03, 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., March 03, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will present a clinical and...
Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer
February 23, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced that John Temperato has joined Melinta as President and Chief Operating Officer. Prior to joining Melinta,...
Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia
January 06, 2016 08:00 ET
|
Melinta Therapeutics
New Haven, CT, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat bacterial infections, announced the initiation of an...